PCI Pharma Services operates 38 pharmaceutical manufacturing and development facilities across seven countries, producing therapies that move through clinical trials to commercial distribution. With 8,500+ personnel handling everything from formulation development to packaging, the attack surface spans regulated manufacturing environments, clinical trial data systems, supply chain integration points, and quality management infrastructure that must satisfy FDA, EMA, and other regulatory frameworks. The threat model here is straightforward: any compromise of manufacturing systems could contaminate product batches, while breaches of clinical trial data or supply chain systems create both patient safety risks and massive regulatory exposure.
The company supports 90+ product launches annually, meaning security teams must maintain operational technology (OT) security across pharmaceutical manufacturing lines, protect electronic batch records and quality management systems, and secure integrations with customers' value chains. Regulatory compliance isn't optional - GMP environments require validated systems, audit trails, and controls that meet 21 CFR Part 11 standards for electronic records. The technical domains span pharmaceutical development systems, manufacturing execution systems (MES), laboratory information management systems (LIMS), and clinical trial management platforms, all operating under continuous regulatory scrutiny.
With facilities in the US, Canada, UK, Ireland, Germany, Spain, and Australia, the infrastructure operates across multiple regulatory jurisdictions with different data sovereignty requirements. The company has over 50 years in healthcare services, suggesting legacy systems that likely require modernization alongside newer cloud-based clinical and supply chain platforms. Security architecture must account for both operational continuity in manufacturing environments where downtime means product loss, and the protection of highly sensitive clinical trial data and proprietary drug formulations.
